PTCA199-5: Thalidomide to Chemotherapy Related Nausea and Vomiting in Pancreatic Cancer

Sponsor

Fudan University (Other)

Overall Status

Not yet recruiting

CT.gov ID

NCT06017284

Collaborator

(none)

100

Enrollment

Arms

Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

The purpose of this study is to evaluate the efficacy of thalidomide on improving the quality of life for metastatic pancreatic cancer patients receiving gemcitabine and nab-paclitaxel chemotherapy.

Condition or Disease	Intervention/Treatment	Phase
Pancreatic Cancer Stage IV Chemotherapy-induced Nausea and Vomiting	Drug: Thalidomide Drug: Nab paclitaxel Drug: Gemcitabine	Phase 3

Detailed Description

Pancreatic cancer is a highly lethal malignancy with a 5-year survival less than 10%. Approximately 80% of patients with pancreatic cancer are diagnosed at an advanced stage. Chemotherapy is one of the major treatments for advanced pancreatic cancer. The Metastatic Pancreatic Cancer Trial (MPACT) has confirmed the efficacy of gemcitabine combined with nab-paclitaxel as the first-line treatment to metastatic pancreatic cancer. However, the side-effects related to gemcitabine combined with nab-paclitaxel including nausea/vomiting, insomnia, fatigue, nausea, and malnutrition have impaired the tolerability of the regimen.

Thalidomide is an oral medication used to treat a number of cancers (e.g. multiple myeloma), graft-versus-host disease, and many skin disorders (e.g. complications of leprosy such as skin lesions). It caused severe malformations in babies born to mothers taking the drug for morning sickness in the late 1950s and early 1960s. Thalidomide works on the immune system to reduce inflammation. Thalidomide may enhance the tolerability of chemotherapy by reducing nausea/vomiting, improving sleeping quality, alleviating pain, and thus improving quality of life for patients with pancreatic cancer.

The purpose of this study is to evaluate the efficacy of Thalidomide on improving the quality of life for metastatic pancreatic cancer patients receiving gemcitabine and nab-paclitaxel chemotherapy. One hundred patients will be randomly assigned to the experimental group (gemcitabine combined with nab-paclitaxel, Thalidomide) or the control group (gemcitabine combined with nab-paclitaxel). Rate of nausea/vomiting, index of sleep quality, severity of pain, quality of life, and overall survival are measured every four weeks.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

100 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Thalidomide to Chemotherapy Related Nausea and Vomiting in Pancreatic Cancer

Anticipated Study Start Date :

Nov 1, 2023

Anticipated Primary Completion Date :

Nov 30, 2025

Anticipated Study Completion Date :

Nov 30, 2026

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Chemotherapy + Thalidomide nab-paclitaxel (120 mg per square meter of body-surface area) followed by gemcitabine (1000 mg per square meter) on days 1, 8, and 15 every 4 weeks. Thalidomide 100 mg/day, once a day, orally intake at night.	Drug: Thalidomide Thalidomide 100 mg/day, once a day, orally intake at night. Drug: Nab paclitaxel nab-paclitaxel (120 mg per square meter of body-surface area) on days 1, 8, and 15 every 4 weeks. Drug: Gemcitabine gemcitabine (1000 mg per square meter) on days 1, 8, and 15 every 4 weeks.
Active Comparator: Chemotherapy nab-paclitaxel (120 mg per square meter of body-surface area) followed by gemcitabine (1000 mg per square meter) on days 1, 8, and 15 every 4 weeks. .	Drug: Nab paclitaxel nab-paclitaxel (120 mg per square meter of body-surface area) on days 1, 8, and 15 every 4 weeks. Drug: Gemcitabine gemcitabine (1000 mg per square meter) on days 1, 8, and 15 every 4 weeks.

Arm

Intervention/Treatment

Experimental: Chemotherapy + Thalidomide

nab-paclitaxel (120 mg per square meter of body-surface area) followed by gemcitabine (1000 mg per square meter) on days 1, 8, and 15 every 4 weeks. Thalidomide 100 mg/day, once a day, orally intake at night.

Drug: Thalidomide

Thalidomide 100 mg/day, once a day, orally intake at night.

Drug: Nab paclitaxel

nab-paclitaxel (120 mg per square meter of body-surface area) on days 1, 8, and 15 every 4 weeks.

Drug: Gemcitabine

gemcitabine (1000 mg per square meter) on days 1, 8, and 15 every 4 weeks.

Active Comparator: Chemotherapy

nab-paclitaxel (120 mg per square meter of body-surface area) followed by gemcitabine (1000 mg per square meter) on days 1, 8, and 15 every 4 weeks. .

Drug: Nab paclitaxel

nab-paclitaxel (120 mg per square meter of body-surface area) on days 1, 8, and 15 every 4 weeks.

Drug: Gemcitabine

gemcitabine (1000 mg per square meter) on days 1, 8, and 15 every 4 weeks.

Outcome Measures

Primary Outcome Measures

Rate of nausea/vomiting [At the end of Cycle 1 (each cycle is 28 days)]
Rate of nausea/vomiting after every cycle of chemotherapy using the 4-point Likert scale. The range of scale is 0-3 and higher scores mean a worse outcome.

Secondary Outcome Measures

Pain numeric rating scale (NRS) [At the end of Cycle 1 (each cycle is 28 days)]
Change of pain numeric rating scale after every cycle of chemotherapy. The administration of analgesic drugs after every cycle of chemotherapy is recorded. The range of NRS scale is 0-10 and higher scores mean a worse outcome.
Quality of life (QOL) [At the end of Cycle 1 (each cycle is 28 days)]
Change of QOL after every cycle of chemotherapy assessed using European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)
Sleep quality index [At the end of Cycle 1 (each cycle is 28 days)]
Sleep quality index after every cycle of chemotherapy is assessed using Pittsburgh sleep quality index (PSQI)
Overall survival (OS) [At the end of Cycle 1 (each cycle is 28 days)]
OS of subjects from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 80 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Ability to understand and the willingness to sign a written informed consent document.
Age ≥ 18 years and ≤ 80 years.
Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
Histologically or cytologically confirmed metastatic pancreas adenocarcinoma.
Adequate organ performance based on laboratory blood tests.
Presence of at least of one measurable lesion in agreement to Response Evaluation Criteria in Solid Tumors (RECIST) criteria.
The expected survival ≥ 3 months.
Women of childbearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation.

Exclusion Criteria:

Patients who have received any form of anti-tumor therapy.
The diagnosis was confirmed by pathology as non-adenocarcinoma of pancreas.
Inflammation of the digestive tract, including pancreatitis, cholecystitis, cholangitis, etc.
Pregnant or nursing women.
Severe and uncontrollable accompanying diseases that may affect protocol compliance or interfere with the interpretation of results, including active opportunistic infections or advanced (severe) infections, and diabetes that cannot be controlled after adequate clinical anti-hyperglycemia treatment according to guidelines, uncontrollable hypertension, cardiovascular disease (Class III or IV heart failure as defined by the New York Heart Association classification, congestive heart failure (CHF), myocardial infarction in the past 6 months , unstable arrhythmia or unstable angina, cerebral infarction within 3 months, etc).
History of allergic reactions attributed to compounds of similar chemical or biologic composition to gemcitabine, nab-paclitaxel, or other agents used in the study.
Other serious accompanying illnesses, which, in the researcher's opinion, could seriously adversely affect the safety of the treatment.
Patients who are unwilling or unable to comply with study procedures.